Other

US sues to block $28 bn Amgen biopharma acquisition

US regulators filed a lawsuit Tuesday to block biopharmaceutical firm Amgen's proposed $28 billion takeover of drug maker Horizon Therapeutics, saying the transaction would harm consumers.

Oncology & Cancer

Gene score IDs prognosis in metastatic neuroblastoma

(HealthDay)—For children with metastatic MYCN-nonamplified neuroblastoma (NBL-NA) diagnosed at age 18 months or older, increased expression of tumor-associated inflammatory genes seems to correlate with poor prognosis, ...

Medications

FDA approves lower-cost alternative to biotech drug Humira

Federal regulators on Friday approved the first alternative version of the second-best selling drug in the world, Humira, the blockbuster injection used to treat rheumatoid arthritis and other inflammatory diseases.

Oncology & Cancer

Response-guided neoadjuvant chemo beneficial in breast CA

(HealthDay)—For patients with early breast cancer, a response-guided neoadjuvant chemotherapy approach seems beneficial, according to a study published online Sept. 3 in the Journal of Clinical Oncology.

Medications

Valeant steps in to work on psoriasis drug with AstraZeneca

Canadian drugmaker Valeant will work with British competitor AstraZeneca on a potential treatment for psoriasis a few months after biotech giant Amgen said it was ending research on the drug because of a link to suicidal ...

page 2 from 4